DNA HLA Typing at 1st Field Resolution|
UKAS Schedule of Accreditation, Accredited to ISO/IEC 17043:2010 Provider 8351
PURPOSE OF PROGRAMME:
To assess participants' ability to correctly determine HLA alleles at the 1st field level
|DNA||HLA alleles at the 1st field|
|HLA||HLA alleles at the 1st field|
|HLA-A||HLA alleles at the 1st field|
|HLA-B||HLA alleles at the 1st field|
|HLA-C||HLA alleles at the 1st field|
|HLA-DRB1||HLA alleles at the 1st field|
|HLA-DRB4||HLA alleles at the 1st field|
|HLA-DRB5||HLA alleles at the 1st field|
|HLA-DQA1||HLA alleles at the 1st field|
|HLA-DQB1||HLA alleles at the 1st field|
|HLA-DPA1||HLA alleles at the 1st field|
|HLA-DRB3||HLA alleles at the 1st field|
MATERIAL PROVIDED: Blood
DISTRIBUTIONS PER YEAR: 2
SAMPLES PER DISTRIBUTION: 5
FREQUENCY OF DISTRIBUTION: As per Distribution Timetable
PROGRAMME OF ANALYSIS:
Results should be submitted via online data entry or on the official UK NEQAS for H&I result forms, available from the UK NEQAS for H&I website. Results are expected to be returned within the specified reporting period (please refer to results deadline for each distribution on the UK NEQAS for H&I website or Participants Manual). The majority of UK NEQAS for H&I schemes are assessed on a consensus basis, therefore samples are distributed with the assigned value not being determined. Where a reference result is used, this testing is performed alongside or after the close of the EQA scheme. For these reasons UK NEQAS for H&I is unable to disclose results early.
Qualitative analysis. Participants will only be assessed on those alleles that appear in the IMGT/HLA database update from the January two years prior to start of the Scheme
Participating laboratories will be assessed on the loci they designate at registration. The consensus full HLA genotype is determined by at least 75% of laboratories agreeing each allele. A "blank" forms part of the assessment if at least 75% of laboratories report a single allele at a locus. A reference result will be used for DPB1 assessment and for other results failing to reach the 75% consensus level.
Satisfactory performance is obtaining nine or more full HLA genotypes in agreement with the consensus genotypes in a year.
PERSISTENT POOR PERFORMANCE:
Laboratories not meeting the Satisfactory Performance criteria are deemed to have Unsatisfactory Performance and must complete a root cause, corrective and preventative action form.
Histocompatibility & Immunogenetics
The External Quality Assessment Scheme for Histocompatibility and Immunogenetics was founded in 1975 by Dr Heather Dicks and Dr Colin Entwistle at the National Tissue Typing and Reference Laboratory (NTTRL) based at Southmead Hospital in Bristol. In 1989 the Service became known as the UK National External Quality Assessment Service for Histocompatibility and Immunogenetics with Dr Peter Klouda as the service director and Mr Terry Ray as the service manager. The service relocated to a new host organisation in September 2000. UK NEQAS for Histocompatibility and Immunogenetics is now part of the Welsh Blood Service.